ReviewMolecules (Basel, Switzerland)2026
Recent Advances in Small-Molecule-Based Nanovectors for the Treatment of Colorectal Cancer.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a major global health burden, while conventional systemic therapies are limited by toxicity, drug resistance, suboptimal tumour exposure, and pharmacokinetic constraints. Recent advances in nanotechnology have produced diverse nanosystems including liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles, mesoporous silica systems, and other hybrid platforms that can improve drug solubility, stability, biodistribution, controlled release, and tumour-directed delivery. Plant-derived small molecules provide an additional source of structurally diverse anticancer candidates, but their clinical development is often constrained by poor aqueous solubility, rapid metabolism, limited bioavailability, and non-specific toxicity. This review critically examines recent progress in nanoscale delivery systems for CRC and evaluates their potential for delivering plant-derived and other bioactive small molecules. Particular emphasis is placed on passive and active targeting, physicochemical determinants of delivery, platform-specific advantages and limitations, preclinical evidence, and the barriers to clinical translation. The review also highlights the distinction between plant-derived and fungal-derived natural products and identifies opportunities for integrating natural products with responsive and ligand-functionalized nanocarriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.